GleamWall
中文EN

SXTP 60 DEGREES PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1946563 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.8%
TTM net income YoY-4.7%
TTM EPS YoY95.7%
Revenue 3-yr CAGR115.4%
Net income 3-yr CAGR—

Margins

Gross margin24.1%
Operating margin-971.9%
Net margin-921.0%
FCF margin-906.9%
EBITDA margin-964.6%

Returns

ROE-316.7%
ROA-170.7%
ROIC (approx.)-1,197.4%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets75.6%
Debt / equity0.18x
Current ratio1.17x
Interest coverage-1,207.18x

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue12.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$233,235$207,898$162,092$303,385$437,602$100,932$163,552$230,846
Cost of revenue$330,766$151,100$85,715$120,682$537,690$50,051$73,272$118,077
Gross profit-$97,531$56,798$76,377$182,703-$100,088$50,881$90,280$112,769
R&D expense$782,595$598,653$281,464$638,873$786,465$231,912$370,813$613,955
SG&A expense$1.65M$1.73M$1.89M$1.47M$1.53M$1.63M$1.72M$1.61M
Operating income-$2.53M-$2.27M-$2.09M-$1.92M-$2.33M-$1.61M-$1.91M-$2.07M
Interest expense$1,421$1,403$1,389$3,086$1,708$1,221$1,790$1,422
Pretax income-$2.56M-$2.27M-$2.09M-$1.44M-$2.32M-$1.73M-$1.88M-$2.05M
Income tax———-$1,813$250$1,500$63-$501
Net income-$2.56M-$2.26M-$2.09M-$1.44M-$2.32M-$1.73M-$1.88M-$2.05M
EBITDA-$2.51M-$2.25M-$2.08M-$1.90M-$2.31M-$1.60M-$1.90M-$2.06M
EPS (basic)-0.75-0.90-1.28—-2.66-5.01-6.25—
EPS (diluted)-0.75-0.90-1.28—-2.66-5.01-6.25—
Weighted avg. shares (diluted)3.55M2.65M1.73M—918,852368,250320,890—
Balance sheet
Cash & equivalents$306,191$1.02M$3.34M$1.51M$4.12M$1.97M$3.45M$1.66M
Short-term investments———$1.24M$0$0—$1.73M
Receivables$338,494$567,040$335,836$509,644$674,036$295,034$488,243$486,748
Inventory$578,524$877,945$910,603$656,924$527,004$799,421$773,238$442,764
Current assets$2.56M$3.73M$6.26M$4.90M$6.31M$3.84M$5.65M$5.39M
PP&E, net$225,815$242,714$259,665$246,365$227,752$193,879$155,792$149,808
Intangibles$304,031$308,683$243,212$224,361$152,383$143,704$149,785$157,084
Total assets$3.09M$4.28M$6.76M$5.37M$6.69M$4.18M$5.98M$5.76M
Current liabilities$2.19M$1.61M$1.88M$1.85M$2.20M$1.69M$1.80M$1.66M
Short-term debt$3,602$2,003$8,772$11,517$8,772$8,772$8,772$8,772
Long-term debt$150,030$150,030$150,030$144,003$150,000$150,000$150,000$147,119
Total debt$153,632$152,033$158,802$155,520$158,772$158,772$158,772$155,891
Total liabilities$2.34M$1.75M$2.02M$1.99M$2.34M$1.84M$1.95M$1.80M
Shareholders' equity$842,016$2.61M$4.83M$3.46M$4.43M$2.43M$4.11M$4.04M
Net debt-$152,559-$870,573-$3.18M-$1.35M-$3.96M-$1.81M-$3.29M-$1.50M
Shares outstanding1.16M2.66M2.64M1.16M4.10M1.47M1.47M141,749
Cash flow statement
Operating cash flow-$1.45M-$2.23M-$2.74M-$1.69M-$2.11M-$1.45M-$1.60M-$1.64M
Capital expenditure$0$0$30,000$79,881$9,999$47,323$2,678$0
Free cash flow-$1.45M-$2.23M-$2.77M-$1.77M-$2.12M-$1.50M-$1.60M-$1.64M
Investing cash flow-$12,648-$85,984$1.19M-$1.37M-$25,487-$51,684$1.70M-$2,098
Financing cash flow$740,000$0$3.37M$458,614$4.28M$0$1.70M$973
Depreciation & amortization$16,899$16,950$16,700$15,169$12,225$9,236$6,694$5,449
Stock-based compensation$47,802$98,405$124,102$111,961$79,000$78,620$186,763$61,639

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.